-
公开(公告)号：US20210371517A1
公开(公告)日：2021-12-02
申请号：US17097630
申请日：2020-11-13
发明人： Michael C. Jensen
IPC分类号： C07K16/28 , A61K35/17 , C12N5/0783 , C07K14/725 , C07K14/705 , C12N15/85 , A61K35/28 , A61K38/17 , C07K14/71 , C07K14/715 , C07K16/32 , A61K39/395 , C12N9/12
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. In some alternatives, the ligand binding domains binds to CD171.
-
公开(公告)号：US20210324407A1
公开(公告)日：2021-10-21
申请号：US17271814
申请日：2019-08-28
发明人： Michael C. Jensen , Joshua Gustafson , Joseph Cheng , Rachel Wilson , Kamila Sabina Gwiazda , Jeremy Bjelajac
IPC分类号： C12N15/85
摘要： Some embodiments provided herein relate to gene delivery systems and methods using a single plasmid that carries a self-inactivating transposase gene and a corresponding transposon. Some embodiments include nucleic acids having certain sequences, vector including such nucleic acids, and compositions including the vectors.
-
公开(公告)号：US20210186426A1
公开(公告)日：2021-06-24
申请号：US17274137
申请日：2019-09-06
申请人： University of Washington , Seattle Children's Hospital (DBA Seattle Children's Research Institute)
摘要： Examples of systems and methods described herein may estimate a state of the ear canal of a patient utilizing a smart phone by characterizing acoustic waveforms reflected off the patient's eardrum. Examples may include an acoustic focusing apparatus that may be connected to a smart phone to provide acoustic signals to and receive reflected signals from an ear canal.
-
34.发明申请公开(公告)号：US20210139583A1
公开(公告)日：2021-05-13
申请号：US17096138
申请日：2020-11-12
发明人： Michael C. Jensen , Suzie Pun , Nataly Kacherovsky
IPC分类号： C07K16/28 , A61K35/17 , C12N5/0783 , C07K14/725 , C07K14/705 , C12N15/85 , A61K35/28 , A61K38/17 , C07K14/71 , C07K14/715 , C07K16/32 , A61K39/395 , C12N9/12
摘要： Aspects of the invention described herein include methods of treating, inhibiting, ameliorating and/or eliminating a virus or cancer cells in a subject utilizing genetically engineered human T-cells having receptors for a molecule presented by the virus or the cancer cells, wherein the genetically engineered T cells are isolated utilizing a two-stage MTX selection that employs increasing concentrations of MTX.
-
公开(公告)号：US20210017246A1
公开(公告)日：2021-01-21
申请号：US16979475
申请日：2019-03-12
IPC分类号： C07K14/54 , C07K14/725
摘要： Some embodiments of the methods and compositions provided herein include cells having membrane-tethered, IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wild-type IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.
-
公开(公告)号：US20150038684A1
公开(公告)日：2015-02-05
申请号：US14376610
申请日：2013-02-13
发明人： Michael Jensen
CPC分类号： C07K16/2803 , A61K35/17 , A61K38/00 , A61K38/179 , A61K47/6849 , A61K2039/505 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K16/2887 , C07K16/2896 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N7/00 , C12N2510/00 , C12N2740/15021 , C12N2740/15043 , Y02A50/473
摘要： The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.
摘要翻译： 本发明涉及双特异性嵌合抗原受体，其包含：（a）至少两个抗原特异性靶向区; （b）细胞外间隔区; （c）跨膜结构域; （d）至少一个共刺激结构域; 和（e）细胞内信号结构域，其中每个抗原特异性靶向区包含抗原特异性单链Fv（scFv）片段，并结合不同的抗原，并且其中所述双特异性嵌合抗原受体与治疗对照共表达 。 本发明还提供双特异性嵌合抗原受体的方法和用途。
-
37.发明公开公开(公告)号：US20240316310A1
公开(公告)日：2024-09-26
申请号：US18608428
申请日：2024-03-18
申请人： University of Washington , SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE
发明人： Courtnie Paschall , Jeffrey Andrew Herron , Emmanuel Tanumihardja , Rajesh P.N. Rao , Jason Scott Hauptman , Jeffrey G. Ojemann
IPC分类号： A61M21/02
CPC分类号： A61M21/02 , A61M2205/04 , A61M2205/33 , A61M2210/0693 , A61M2230/63
摘要： An extended reality (XR) neural perceptual feedback (NPF) system includes an XR system and a neural interface. The XR system presents a virtual environment to the user and monitors the user's interactions with the virtual environment. Based on the interaction with the virtual environment, the neural interface applies stimulation to the nervous system of the user. For example, a stimulation pattern may be selected based on the type of interaction, what type of virtual object the interaction was with, or combinations thereof. The stimulation may cause a percept in the user, allowing them to have perceptual feedback from interacting with the virtual environment. The neural interface may also be used to direct interactions within the virtual environment, for example using neural signal decoding to determine how to update the virtual environment.
-
公开(公告)号：US20240075069A1
公开(公告)日：2024-03-07
申请号：US18459302
申请日：2023-08-31
申请人： ENDOCYTE, INC. , PURDUE RESEARCH FOUNDATION , SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE)
发明人： Philip Stewart LOW , Haiyan CHU , Yingjuan June LU , Christopher Paul LEAMON , Leroy W. WHEELER, II , Michael C. JENSEN , James MATTHAEI
IPC分类号： A61K35/17 , A61K9/00 , A61K31/365 , A61K31/519 , A61K38/17 , A61P35/00 , C07K14/725 , C07K16/44 , C07K16/46 , C12N5/0783
CPC分类号： A61K35/17 , A61K9/0019 , A61K9/0053 , A61K31/365 , A61K31/519 , A61K38/1774 , A61P35/00 , C07K14/7051 , C07K16/44 , C07K16/46 , C12N5/0638 , C07K2317/622
摘要： The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
39.发明公开公开(公告)号：US20240033300A1
公开(公告)日：2024-02-01
申请号：US18336248
申请日：2023-06-16
IPC分类号： A61K35/545 , C12N15/10 , C12N15/66 , C12N15/85 , A61K48/00 , A61P37/06 , A61K38/20 , C12N5/0789 , C12N15/52
CPC分类号： A61K35/545 , C12N15/102 , C12N15/66 , C12N15/85 , A61K48/00 , A61P37/06 , A61K38/2013 , C12N5/0647 , C12N15/52
摘要： Disclosed are methods of making a genetically cell that expressed FOXP3 and methods of treatment. In some embodiments, the method comprises providing a first nucleotide sequence, wherein the first nucleotide sequence comprises a coding strand, the coding strand comprising one or more regulatory elements and a FOXP3 gene or portion thereof providing a nuclease and performing a gene editing process on the first nucleotide sequence, which edits said one or more regulatory elements, and optionally edits the FOXP3 gene or portion thereof. Methods of treating a subject suffering from an autoimmune disease and subjects suffering the effects of organ transplantation are also provided.
-
公开(公告)号：US20230374104A1
公开(公告)日：2023-11-23
申请号：US18030476
申请日：2021-10-07
发明人： Michael C. Jensen , Adam Johnson , James Rosser
IPC分类号： C07K14/705 , C07K14/725
CPC分类号： C07K14/70596 , C07K14/7051
摘要： Some embodiments of the methods and compositions provided herein relate to chimeric proteins comprising a programmed cell death protein 1 (PD 1) extracellular domain and an intracellular immunostimulatory domain. Some embodiments include a cell containing a PD 1 chimeric polypeptide and a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises a ligand binding domain capable of specifically binding to a target antigen on a solid tumor. More embodiments relate to therapies to treat, inhibit or ameliorate certain disorders, such as a cancer, such as a solid tumor.
-
-
-
-
-
-
-
-
-
搜索结果
81 条记录 (耗时 0.033 秒)
